Skip to main content
Clinical Trials/NCT05728931
NCT05728931
Active, not recruiting
Not Applicable

New Biomarkers in Auto-immune Encephalitis and Neurological Paraneoplastic Syndromes

Hospices Civils de Lyon1 site in 1 country210 target enrollmentJanuary 15, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Paraneoplastic Neurological Syndrome
Sponsor
Hospices Civils de Lyon
Enrollment
210
Locations
1
Primary Endpoint
Description of new biomarkers
Status
Active, not recruiting
Last Updated
3 years ago

Overview

Brief Summary

Autoimmune encephalitis (AE) and paraneoplastic neurological syndromes (PNS) are rare neuroimmune syndromes with a wide range of clinical presentation but without pathognomonic clinical sign facilitating the diagnosis. A lot of differential diagnoses are possible such as neurodegenerative diseases or viral infections. Although rare the diagnosis of AE or PNS is essential because despite severe neurological symptoms, patients can be cured by appropriate immunotherapy. Autoantibodies highly specific of AE and PNS has been described in the serum and cerebrospinal fluid of the patients and can be used as biomarkers of the disease. Their presence can predict an autoimmune origin and in many cases a good prognosis after immunotherapy. However, if some autoantibodies are now well-characterized and industrial kits have been developed to detect them, in numerous cases of highly suspect AE or PNS no specific autoantibodies are identified leading frequently to an inappropriate treatment. Furthermore, as the mechanisms of AE and PNS is still unknown, treatments are not optimal and in some cases inefficient. There is no prognosis biomarker able to predict the patient's sensitivity to immunotherapy and there are only few clues to know how the immune system can provoke the neuropsychiatric symptoms observed in the patients. The investigators will use this project to better characterize AE and PNS patients to identify new diagnostic and prognostic biomarkers and develop new diagnostic tools.

Registry
clinicaltrials.gov
Start Date
January 15, 2022
End Date
January 15, 2032
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Description of new biomarkers

Time Frame: Baseline

Results of diagnostics tests for each patient, description of marking

Study Sites (1)

Loading locations...

Similar Trials